PodcastIntel
Sign in Get Started Free
HCPLive
HCPLive

Why Zasocitinib Outperformed Deucravacitinib in New Plaque Psoriasis Data

Oct 6, 2026 · 0:05:07
✨ AI Summary
  • Zasocitinib shows promise for clear skin in plaque psoriasis.
  • Head-to-head data presented at EADV Congress favored Zasocitinib.
  • Oral TYK2 inhibitor aims for complete skin clearance.

Guests on This Episode

LG
Linda Stein Gold
2 podcast appearances

More from HCPLive

View all episodes →

Get AI Summaries for Every New Episode

Subscribe to HCPLive and get AI summaries, guest tracking, and email digests delivered automatically.

Sign Up Free →